Status of prophylactic and therapeutic genital herpes vaccines
Status of prophylactic and therapeutic genital herpes vaccines
复制标题
DOI：
10.1016/j.coviro.2014.02.006
复制
发表时间：
2014-06-01
影响因子：
5.9
通讯作者：
Friedman, Harvey M.
中科院分区：
文献类型：
--
作者：
Awasthi, Sita;Friedman, Harvey M.
生殖器疱疹的危害有哪些？大约五分之一的14岁至49岁的美国妇女是HSV-2血清阳性。开发有效的生殖器疱疹疫苗是全球健康的必要性，这是基于生殖器疱疹对某些人造成的精神痛苦，患有生殖器疱疹的孕妇有将感染传播给新生儿的风险，以及观察到HSV-2感染与艾滋病毒感染概率增加3倍至4倍有关。我们回顾了用于评估生殖器疱疹候选疫苗的临床前动物模型的优势和局限性以及预防性和治疗性疫苗的目标。我们还讨论了目前候选疫苗的管道和从过去的临床试验中吸取的经验教训，这些经验教训可以刺激新的策略，研究设计和终点确定。
A half billion people have genital herpes infections worldwide. Approximately one-fifth of American women between ages 14 and 49 are HSV-2 seropositive. The development of an effective genital herpes vaccine is a global health necessity based on the mental anguish genital herpes causes for some individuals, the fact that pregnant women with genital herpes risk transmitting infection to their newborn children, and the observation that HSV-2 infection is associated with a 3-fold to 4-fold increased probability of HIV acquisition. We review the strengths and limitations of preclinical animal models used to assess genital herpes vaccine candidates and the goals of prophylactic and therapeutic vaccines. We also discuss the current pipeline of vaccine candidates and lessons learned from past clinical trials that serve as a stimulus for new strategies, study designs and endpoint determinations.